Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Recruiting Phase 4 Interventional Study
Phobia, Social
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 55
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Other
Participants needed
50 (estimated)
Sponsor
Massachusetts Institute of Technology · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Ability and willingness to provide written informed consent. * Sufficiently fluent in English to participate in the trial. * Between 18-55 years of age (inclusive). * Right-hand dominant. * Current medications are stable for past 30 days (no changes to dose or frequency). * Ne…
Contacts

Omar Rutledge, MS

617-324-2898

orutledge@mit.edu

CONTACT